 Kaplan-Meier Estimate
"Kaplan-Meier Estimate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)
| Descriptor ID |
D053208
|
| MeSH Number(s) |
E05.318.740.998.650 N05.715.360.750.795.650 N06.850.520.830.998.650
|
| Concept/Terms |
Kaplan-Meier Estimate- Kaplan-Meier Estimate
- Estimate, Kaplan-Meier
- Kaplan-Meier Test
- Kaplan Meier Test
- Test, Kaplan-Meier
- Product-Limit Method
- Method, Product-Limit
- Methods, Product-Limit
- Product Limit Method
- Product-Limit Methods
- Kaplan-Meier Analysis
- Analysis, Kaplan-Meier
- Kaplan Meier Analysis
Kaplan-Meier Survival Curves- Kaplan-Meier Survival Curves
- Curves, Kaplan-Meier Survival
- Kaplan Meier Survival Curves
- Survival Curves, Kaplan-Meier
|
Below are MeSH descriptors whose meaning is more general than "Kaplan-Meier Estimate".
Below are MeSH descriptors whose meaning is more specific than "Kaplan-Meier Estimate".
This graph shows the total number of publications written about "Kaplan-Meier Estimate" by people in this website by year, and whether "Kaplan-Meier Estimate" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 1 | 5 | 6 | | 2014 | 0 | 3 | 3 | | 2015 | 0 | 1 | 1 | | 2016 | 0 | 2 | 2 | | 2017 | 0 | 3 | 3 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Kaplan-Meier Estimate" by people in Profiles.
-
Brown DD, Roem J, Ng DK, Reidy KJ, Kumar J, Abramowitz MK, Mak RH, Furth SL, Schwartz GJ, Warady BA, Kaskel FJ, Melamed ML. Low Serum Bicarbonate and CKD Progression in Children. Clin J Am Soc Nephrol. 2020 06 08; 15(6):755-765.
-
Winnicki E, Johansen KL, Cabana MD, Warady BA, McCulloch CE, Grimes B, Ku E. Higher eGFR at Dialysis Initiation Is Not Associated with a Survival Benefit in Children. J Am Soc Nephrol. 2019 08; 30(8):1505-1513.
-
Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS. Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531. Blood. 2017 08 17; 130(7):943-945.
-
Fuhrman DY, Schneider MF, Dell KM, Blydt-Hansen TD, Mak R, Saland JM, Furth SL, Warady BA, Moxey-Mims MM, Schwartz GJ. Albuminuria, Proteinuria, and Renal Disease Progression in Children with CKD. Clin J Am Soc Nephrol. 2017 Jun 07; 12(6):912-920.
-
Vujkovic M, Attiyeh EF, Ries RE, Goodman EK, Ding Y, Kavcic M, Alonzo TA, Wang YC, Gerbing RB, Sung L, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Aplenc R. Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report. Blood. 2017 06 08; 129(23):3051-3058.
-
Cuna A, Govindarajan S, Oschman A, Dai H, Brophy K, Norberg M, Truog W. A comparison of 7-day versus 10-day course of low-dose dexamethasone for chronically ventilated preterm infants. J Perinatol. 2017 03; 37(3):301-305.
-
Gerbing RB, Alonzo TA, Sung L, Gamis AS, Meshinchi S, Plon SE, Bertuch AA, Gramatges MM. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. J Clin Oncol. 2016 11 01; 34(31):3766-3772.
-
Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group. Clin Cancer Res. 2015 Jul 15; 21(14):3187-95.
-
McCulloh RJ, Koster MP, Yin DE, Milner TL, Ralston SL, Hill VL, Alverson BK, Biondi EA. Evaluating the use of blood cultures in the management of children hospitalized for community-acquired pneumonia. PLoS One. 2015; 10(2):e0117462.
-
Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children?s Oncology Group trial AAML0531. J Clin Oncol. 2014 Sep 20; 32(27):3021-32.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|